NASDAQ:MNOV

MediciNova Stock Forecast, Price & News

$4.62
+0.12 (+2.67 %)
(As of 04/22/2021 12:22 PM ET)
Add
Compare
Today's Range
$4.46
Now: $4.62
$4.62
50-Day Range
$4.39
MA: $5.31
$8.74
52-Week Range
$4.28
Now: $4.62
$13.25
Volume4,277 shs
Average Volume798,975 shs
Market Capitalization$224.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
MediciNova logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500
Employees9
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.71 per share

Profitability

Net Income$-12,940,000.00

Miscellaneous

Market Cap$224.91 million
Next Earnings Date4/22/2021 (Estimated)
OptionableOptionable

Headlines

MediciNova Receives Gene Therapy Milestone Payments
April 22, 2021 |  finance.yahoo.com
Short Interest in MediciNova, Inc. (NASDAQ:MNOV) Grows By 36.4%
April 2, 2021 |  americanbankingnews.com
Why MediciNova Shares Jumped 111% Today
March 11, 2021 |  msn.com
Why MediciNova Stock Skyrocketed Today
March 10, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.24 out of 5 stars

Medical Sector

882nd out of 2,024 stocks

Pharmaceutical Preparations Industry

415th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$4.62
+0.12 (+2.67 %)
(As of 04/22/2021 12:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MediciNova (NASDAQ:MNOV) Frequently Asked Questions

Is MediciNova a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MediciNova stock.
View analyst ratings for MediciNova
or view top-rated stocks.

What stocks does MarketBeat like better than MediciNova?

Wall Street analysts have given MediciNova a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MediciNova wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting MediciNova?

MediciNova saw a increase in short interest in March. As of March 15th, there was short interest totaling 3,150,000 shares, an increase of 36.4% from the February 28th total of 2,310,000 shares. Based on an average trading volume of 880,600 shares, the days-to-cover ratio is currently 3.6 days.
View MediciNova's Short Interest
.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, April 22nd 2021.
View our earnings forecast for MediciNova
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) posted its earnings results on Thursday, February, 18th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01.
View MediciNova's earnings history
.

How has MediciNova's stock been impacted by COVID-19?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MNOV stock has increased by 39.2% and is now trading at $4.58.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MNOV?

2 equities research analysts have issued 12 month price objectives for MediciNova's shares. Their forecasts range from $11.00 to $15.00. On average, they anticipate MediciNova's stock price to reach $13.00 in the next year. This suggests a possible upside of 183.8% from the stock's current price.
View analysts' price targets for MediciNova
or view top-rated stocks among Wall Street analysts.

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 71, Pay $803.37k)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer & Director (Age 55, Pay $588.57k)
  • Mr. Edward C. Stepanow Jr., CFO & Principal Financial Officer (Age 54)
  • Mr. John O'Neil CPA, Controller

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $4.58.

How much money does MediciNova make?

MediciNova has a market capitalization of $222.96 million.

How many employees does MediciNova have?

MediciNova employs 9 workers across the globe.

What is MediciNova's official website?

The official website for MediciNova is medicinova.com.

Where are MediciNova's headquarters?

MediciNova is headquartered at 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.